Bausch & Lomb Incorporated Product Pipeline Analysis

Publication Date	August 2008
Publisher	Global Markets Direct
Product Type	Report
Pages	77
ISBN Number	not applicable
Product Code	GMD04658

Price

£490.00
approximately: $749 | €546

PDF

Order above formats by FAX

Summary

This report is an insightful source for data, analysis and strategic insights into a Bausch & Lomb Incorporated's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

Details of development stage by sector and equipment type.
Pipeline products grouped by therapy area, development stage and trial phase.
Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
Product updates covering estimated approval dates and estimated launch dates.
Descriptions of novel technologies relating to pipeline products of the company.
Patents and patent applications covered for the product.
News updates on key events relating to the product and its development.

Reasons to buy

A single source to fulfill competitor information relating to products in development.
Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

Access clinical trial information to map trial results and plan targeted marketing activities.
Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
Identification of potential investment opportunities.
Build up knowledge base for potential distribution and marketing partners.
Helps avoid patent infringement.
Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

Content

1 List of Tables
- 1.2 List of Figures
2 Company Snapshot
- 2.1 Key Information
- 2.2 Company Overview
- 2.3 Financial Performance
3 Business Description
- 3.1 Business Overview
- 3.2 Cataract and Vitreoretinal Surgery Product Category
  - 3.2.1 Overview
  - 3.2.2 Financials
- 3.3 Contact Lenses Product Category
  - 3.3.1 Overview
  - 3.3.2 Financials
  - 3.3.3 Market View
- 3.4 Lens Care Product Category
  - 3.4.1 Overview
  - 3.4.2 Financials
  - 3.4.3 Market View
  - 3.4.4 Key Strategies
- 3.5 Pharmaceuticals Category
  - 3.5.1 Overview
  - 3.5.2 Financials
  - 3.5.3 Key Strategies
- 3.6 Refractive Surgery Product Category
  - 3.6.1 Overview
  - 3.6.2 Financials
  - 3.6.3 Key Strategies
- 3.7 Major Products and Services
  - 3.7.1 Overview
4 History
5 Business Strategy
- 5.1 Mission Statement
- 5.2 Strategy
- 5.3 Corporate Social Responsibility
  - 5.3.1 Overview
  - 5.3.2 Specific CSR Initiatives
6 Value Chain Analysis
- 6.1 Manufacturing
  - 6.1.1 In House Manufacturing
  - 6.1.2 Outsourcing
- 6.2 Product Development
  - 6.2.1 Regulatory Approvals
  - 6.2.2 Clinical Trials
  - 6.2.3 Research and Development
- 6.3 Sales and Marketing
  - 6.3.1 Partnerships and Alliances
  - 6.3.2 Licensing Agreements
  - 6.3.3 E-distribution
7 Competitors
8 Share Holding Structure
9 Key Employees
10 Key Employee Biographies
11 Locations And Subsidiaries
- 11.1 Head Office
- 11.2 Other Locations & Subsidiaries
12 Recent Developments
- 12.1 Financial Announcements
  - 12.1.1 Aug 08, 2007: Bausch & Lomb Reports Q2 2007 Results
  - 12.1.2 Jul 24, 2007: Bausch & Lomb Declares Quarterly Dividend
  - 12.1.3 May 10, 2007: Bausch & Lomb Preliminary Q1 2007 Results
  - 12.1.4 May 01, 2007: Bausch & Lomb Declares Quarterly Dividend
  - 12.1.5 Mar 06, 2007: Bausch & Lomb Reports Preliminary Q4 And 2006 Results
  - 12.1.6 Feb 26, 2007: Bausch & Lomb Declares Quarterly Dividend
  - 12.1.7 Nov 09, 2006: Bausch & Lomb Reports Preliminary Q3 2006 Results
  - 12.1.8 Nov 07, 2006: Bausch & Lomb Declares Quarterly Dividend
  - 12.1.9 Jul 25, 2006: Bausch & Lomb Declares Quarterly Dividend
  - 12.1.10 May 02, 2006: Bausch & Lomb Declares Quarterly Dividend
- 12.2 Corporate Communications
  - 12.2.1 Jul 23, 2008: Bausch & Lomb Appoints CIO
  - 12.2.2 Jul 01, 2008: Bausch & Lomb Appoints CTO
  - 12.2.3 Jun 24, 2008: Bausch & Lomb Appoints Vice President, Global Clinical & Medical Affairs And Professional Services, Vision Care
  - 12.2.4 May 05, 2008: Bausch & Lomb Announces Management Changes
  - 12.2.5 Mar 06, 2008: Bausch & Lomb Appoints CVP, CHRO
  - 12.2.6 Feb 05, 2008: Bausch & Lomb Appoints New Directors
  - 12.2.7 Jan 23, 2008: Bausch & Lomb Appoints New CEO
  - 12.2.8 Nov 20, 2007: Bausch & Lomb Appoints Corporate VP And General Counsel
  - 12.2.9 Oct 04, 2007: Bausch & Lomb Appoints Corporate Vice President And President, Asia Pacific Region
  - 12.2.10 Jul 05, 2007: Bausch & Lomb Appoints Corporate Vice President And President, US Vision Care
  - 12.2.11 May 23, 2007: Bausch & Lomb Appoints Vice President, Global R&D Vision Care
  - 12.2.12 Mar 19, 2007: Bausch & Lomb CFO Retires
  - 12.2.13 Mar 19, 2007: Bausch & Lomb Appoints New CFO
  - 12.2.14 Feb 19, 2007: Bausch & Lomb Adds New Board Member
  - 12.2.15 Jan 05, 2007: Bausch & Lomb Announces Management Changes
  - 12.2.16 Dec 22, 2006: Bausch & Lombs Listing On NYSE Extended
  - 12.2.17 Apr 19, 2006: Bausch & Lomb Names New President For Its Asia Region
- 12.3 Legal and Regulatory
  - 12.3.1 Jun 20, 2008: Bausch & Lomb Sues Lexington Insurance
  - 12.3.2 May 21, 2008: Bausch & Lomb Sued In St. Clair County
  - 12.3.3 Aug 20, 2007: Bausch & Lomb And Alcon Settle Advertising Lawsuit
  - 12.3.4 Jul 02, 2007: Bausch & Lomb Sued By Parker Waichman
  - 12.3.5 Jun 26, 2007: Bausch & Lomb Files Suit Against Alcon
  - 12.3.6 Nov 06, 2006: Bausch & Lomb Receives FDA Warning Letter Related To Inspection At Greenville
- 12.4 Government and Public Interest
  - 12.4.1 Jun 10, 2008: FDA Panel Recommends Stricter Contact Lens Labeling
- 12.5 Product News
  - 12.5.1 Apr 11, 2008: Bausch & Lomb To Donate Up To $400,000 to Susan G. Komen for the Cure Through ReNu MultiPlus Solution Campaign
  - 12.5.2 Apr 09, 2008: Interim results of hydrophilic acrylic IOL show good visual function, centration
  - 12.5.3 Apr 07, 2008: Bausch & Lomb Lens Wins 2008 Medical Design Excellence Awards Competition
  - 12.5.4 Apr 07, 2008: Bausch & Lomb Lens Wins 2008 Medical Design Excellence Awards Competition
  - 12.5.5 Apr 02, 2008: Gift Of Sight Given To 100 People In 100 Minutes
  - 12.5.6 Sep 26, 2007: Bausch & Lomb Partners with Susan G. Komen for the Cure to Fight Breast Cancer
  - 12.5.7 Sep 26, 2007: Bausch & Lomb Partners with Susan G. Komen for the Cure to Fight Breast Cancer
  - 12.5.8 Sep 07, 2007: Bausch & Lomb Launches The Stellaris Vision Enhancement System In Europe at ESCRS 2007
  - 12.5.9 Jul 13, 2007: The Five Myths of Monovision Correction of Presbyopia
  - 12.5.10 May 31, 2007: Reversible Speculum
  - 12.5.11 Jan 18, 2007: Akreos MI-60 Lens European Launch
  - 12.5.12 Dec 13, 2006: Comparison of Pentacam and Orbscan IIz on Posterior Curvature Topography Measurements in Keratoconus Eyes
  - 12.5.13 Dec 01, 2006: Devgan Cataract System
  - 12.5.14 Nov 11, 2006: Bausch & Lomb Showcases New Technologies At American Academy Of Ophthalmology Annual Meeting
  - 12.5.15 Nov 11, 2006: Bausch & Lomb Showcases New Technologies at American Academy of Ophthalmology Annual Meeting
  - 12.5.16 Sep 01, 2006: Fluidics and Heat Generation of Alcon Infiniti and Legacy, Bausch & Lomb Millennium, and Advanced Medical Optics Sovereign Phacoemulsification Systems
  - 12.5.17 Aug 08, 2006: Bausch & Lomb Receives FDA Approval for Plasma Treatment of Gas-Permeable Contact Lenses
  - 12.5.18 Aug 07, 2006: MAXSIGHT In News
  - 12.5.19 Aug 05, 2006: MAXSIGHT MAKING NEWS
  - 12.5.20 Jul 15, 2006: Nike Maxsight sees sport better
  - 12.5.21 May 15, 2006: Surgeons describe performance of Zyoptix XP device compared with other flap-creation technology
  - 12.5.22 Feb 23, 2006: Bausch & Lomb GP Materials Receive Expanded FDA Post-Surgical Indications
  - 12.5.23 Feb 23, 2006: BostonXO, and EO Gas Permeable Contact Lenses Receive Clearance for Use Following Penetrating Keratoplasty or Refractive Surgeries
  - 12.5.24 Feb 01, 2006: Cataract surgery and lens implantation
  - 12.5.25 Jan 31, 2006: Anika Therapeutics--An Injection for Growth
  - 12.5.26 Nov 18, 2005: Specialty Lenses Continue to Lead Contact Lens Growth
  - 12.5.27 Nov 01, 2005: Posterior capsule opacification after implantation of a hydrogel intraocular lens
  - 12.5.28 Oct 31, 2005: Determining corneal power using Orbscan II videokeratography for intraocular lens calculation after excimer laser surgery for myopia
  - 12.5.29 Oct 12, 2005: Bausch & Lomb Offers Retina Surgeons Easy Access to Next-Generation Millennium TSV25 Technology Upgrades
  - 12.5.30 Oct 10, 2005: The Zyoptix XP: An Advance in Mechanical Microkeratome Technology
  - 12.5.31 Sep 03, 2005: Global contact lens revenues are expected to grow
  - 12.5.32 Feb 01, 2005: Reproducibility of Self-Measured Intraocular Pressure With the Phosphene Tonometer in Patients With Ocular Hypertension and Early to Advanced Glaucoma
  - 12.5.33 Dec 31, 2004: Performance of SofLens
  - 12.5.34 Dec 10, 2004: Millennium Phaco System Undergoes Enhancements
  - 12.5.35 Aug 08, 2004: Contact Lens
  - 12.5.36 Apr 04, 2004: Bausch & Lomb and CIBA Vision Announce Final Global Settlement of Patent Litigation
  - 12.5.37 Mar 27, 2004: Growth in revenue by addition of Soflens to our contact lens portfolio
  - 12.5.38 Dec 03, 2003: The Effect of Artificial Tears on Visual Performance in Normal Subjects Wearing Contact Lenses
  - 12.5.39 Nov 12, 2003: In vitro and Ex Vivo Wettability
  - 12.5.40 Jun 03, 2003: Higher Order Ocular Aberrations After Cycloplegic and Non-cycloplegic Pupil Dilation
  - 12.5.41 Jun 02, 2003: Minimally Invasive Vitreoretinal Surgery by Small 25-ga instruments
  - 12.5.42 Feb 12, 2003: Federal Circuit Court Upholds Lower Court Decision Preventing Sale of PureVision Contact Lenses in the U.S
  - 12.5.43 Dec 12, 2002: Doctor and patient using the Proview eye pressure monitor provide equal reliability
  - 12.5.44 May 14, 2002: Zero Compression Heads for Hansatome Microkeratome
  - 12.5.45 Mar 28, 2002: AMVISC PRODUCTS
  - 12.5.46 Dec 26, 2001: Cataract/Vitreoretinal Surgery
  - 12.5.47 Aug 24, 2000: Vision Care: Expectations for category growth have moderated
  - 12.5.48 Jun 14, 1999: Bausch & Lomb and Control Delivery Systems Agree to Develop Breakthrough Therapeutic Products for Severe Eye Diseases
  - 12.5.49 Dec 31, 1996: Class action complaints
  - 12.5.50 Jul 11, 1996: NORVIR/INVIRASE AIDS Study Shows Promising Early Results
  - 12.5.51 Dec 08, 1995: Chiron Vision Files FDA Committee Recommendation To Approve Vitrasert Implant
  - 12.5.52 Sep 10, 1995: Legal Proceedings
- 12.6 Clinical Trials
  - 12.6.1 Apr 09, 2008: Interim results of hydrophilic acrylic IOL show good visual function, centration
13 Bausch & Lomb Incorporated Pipeline Products
- 13.1 Bausch & Lomb Incorporated Product Pipeline Analysis
  - 13.1.1 Bausch & Lomb Incorporated Pipeline Products By Equipment Type
  - 13.1.2 Bausch & Lomb Incorporated Pipeline Products By Development Stage
  - 13.1.3 Bausch & Lomb Incorporated Pipeline Products By Therapy Area
  - 13.1.4 Bausch & Lomb Incorporated Pipeline Products By Clinical Trials
  - 13.1.5 Bausch & Lomb Incorporated Pipeline Products By News Summary
- 13.2 Safarazi Elliptical Accommodating IOL
  - 13.2.1 Product Description
  - 13.2.2 Product Status
- 13.3 Akreos AO Micro-Incision sub2-mm lens
  - 13.3.1 Product Description
  - 13.3.2 Product Status
  - 13.3.3 Product Milestone
- 13.4 Akreos AO
  - 13.4.1 Product Description
  - 13.4.2 Product Status
  - 13.4.3 Clinical Trials
  - 13.4.4 Product Patent Details
- 13.5 Akreos MI-60
  - 13.5.1 Product Description
  - 13.5.2 Product Status
  - 13.5.3 Clinical Trials
  - 13.5.4 Product Milestone
  - 13.5.5 Product Patent Details
- 13.6 Zyoptix laser-dynamic rotational eye tracker(Enhacement)
  - 13.6.1 Product Description
14 Appendix
- 14.1 Methodology
  - 14.1.1 Coverage
  - 14.1.2 Secondary Research
  - 14.1.3 Primary Research
  - 14.1.4 Expert Panel Validation
- 14.2 Contact Us
- 14.3 About Global Markets Direct
- 14.4 Disclaimer
1 List of Tables
- Table 1: Bausch & Lomb Incorporated,Key Facts, 2006
- Table 2: Bausch & Lomb Incorporated, Share Holding Structure
- Table 3: Bausch & Lomb Incorporated, Key Employees, 2006
- Table 4: Bausch & Lomb Incorporated, Other Locations
- Table 5: Bausch & Lomb Incorporated Pipeline Products by Equipment Type
- Table 6: Bausch & Lomb Incorporated Pipeline Products By Development Stage
- Table 7: Bausch & Lomb Incorporated Pipeline Products By Therapy Area
- Table 8: Bausch & Lomb Incorporated Pipeline Products By Clinical Trials
- Table 9: Bausch & Lomb Incorporated Pipeline Products By News Summaries
- 1.2 List of Figures
- Figure 1: Bausch & Lomb Incorporated, Value Chain Analysis
- Figure 2: Bausch & Lomb Incorporated Pipeline Products By Development Stage
- Figure 3: Bausch & Lomb Incorporated Pipeline Products By News Summary
- Figure 4: Global Markets Direct Methodology